Harmony Biosciences Q2 FY26 net income rises 90% to $75.4 million; revenue climbs 30% to $261.3 million

• Harmony Biosciences posted Q2 net product revenue of $261.3 million, up 30% year over year, with average patients rising 450 to 8,950.
• Net income climbed to $75.4 million; diluted EPS rose to $1.28.
• Cost of product sold increased 66% to $63.2 million, lifting it to 24.2% of net product revenue due to new Novitium license royalties.
• Reiterated 2026 WAKIX net revenue guidance of $1.0 billion to $1.04 billion, with $962.5 million in cash, cash equivalents and investments at June 30.
• BP-205 Phase 1 SAD data showed favorable PK and safety; Phase 1 MAD data are expected in Q4, with a Phase 1b study starting in Q3.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Harmony Biosciences Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608040730PRIMZONEFULLFEED9803043) on August 04, 2026, and is solely responsible for the information contained therein.